The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Open accessAbstract
Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced‐stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early‐stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2‐years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality‐of‐life. A procedure that has been studied to help reduce the morbidity rate involves pre‐sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum‐based agents are effective due to their increased response to platinum‐based chemotherapy in relapsed cases. These chemo‐drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
The Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits
Polyak, K., & Weinberg, R. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2620 · Cited by 3,302
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial
Prorok, P. C., Andriole, G. L., Bresalier, R. S., Buys, S. S., Chia, D., David Crawford, E., Fogel, R., Gelmann, E. P., Gilbert, F., Hasson, M. A., et al. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00098-2 · Cited by 1,037
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
The Role of ABC Transporters in Clinical Practice
Leonard, G. D., Fojo, T., & Bates, S. E. (2003) · The Oncologist · doi:10.1634/theoncologist.8-5-411 · Cited by 817
Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 754
Chang, K., & Pastan, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 745
Advances in ovarian cancer therapy
Cortez, A. J., Tudrej, P., Kujawa, K. A., & Lisowska, K. M. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3501-8 · Cited by 624
The MRP family of drug efflux pumps
Kruh, G. D., & Belinsky, M. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206953 · Cited by 614
Adoptive cell therapy for the treatment of patients with metastatic melanoma
Rosenberg, S. A., & Dudley, M. E. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.03.002 · Cited by 595
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Felder, M., Kapur, A., Gonzalez-Bosquet, J., Horibata, S., Heintz, J., Albrecht, R., Fass, L., Kaur, J., Hu, K., Shojaei, H., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-129 · Cited by 524
Sp transcription factor family and its role in cancer
Safe, S., & Abdelrahim, M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.006 · Cited by 500
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Pluim, D., van Waardenburg, R. C., Ruevekamp, M. C., Floot, B. G., & Schellens, J. H. M. (1999) · PubMed · Cited by 487
The promise and potential pitfalls of chimeric antigen receptors
Sadelain, M., Brentjens, R., & Rivière, I. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.009 · Cited by 467
Besser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sørensen, P. G., Hansen, M., Sessa, C., de Swart, C. A. M., Hirsch, F. R., Lund, B., & van Houwelingen, H. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3084 · Cited by 428
Kajiyama, H., Shibata, K., Terauchi, M., Yamashita, M., Ino, K., Nawa, A., & Kikkawa, F. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.2.277 · Cited by 410
Clarke-Pearson, D. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0901926 · Cited by 400
ABCG2: determining its relevance in clinical drug resistance
Robey, R. W., Polgar, O., Deeken, J., To, K. W., & Bates, S. E. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9042-6 · Cited by 387
Cancer statistics for adults aged 85 years and older, 2019
DeSantis, C. E., Miller, K. D., Dale, W., Mohile, S. G., Cohen, H. J., Leach, C. R., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21577 · Cited by 370
Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer
De Bacco, F., Luraghi, P., Medico, E., Reato, G., Girolami, F., Perera, T., Gabriele, P., Comoglio, P. M., & Boccaccio, C. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr093 · Cited by 363
Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer
Jaaback, K., Johnson, N., & Lawrie, T. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005340.pub4 · Cited by 359
Cellular mechanisms of multidrug resistance of tumor cells.
Stavrovskaya, A. A. (2000) · PubMed · Cited by 344
Copper Transporters and the Cellular Pharmacology of the Platinum-Containing Cancer Drugs
Howell, S. B., Safaei, R., Larson, C. A., & Sailor, M. J. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.063172 · Cited by 344
Tumor infiltrating lymphocytes in ovarian cancer
Santoiemma, P. P., & Powell, D. J. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1040960 · Cited by 337
BCL2A1: the underdog in the BCL2 family
Vogler, M. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.158 · Cited by 325
Holzer, A. K., Manorek, G. H., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022624 · Cited by 322
Cheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005) · Nature Medicine · doi:10.1038/nm1230 · Cited by 305
Multidrug resistance associated proteins in multidrug resistance
Sodani, K., Patel, A., Kathawala, R. J., & Chen, Z.-S. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10329 · Cited by 300
The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.
Eliopoulos, A. G., Kerr, R. S., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C., & Young, L. S. (1995) · PubMed · Cited by 296
Hassan, R., Remaley, A. T., Sampson, M. L., Zhang, J., Cox, D. D., Pingpank, J., Alexander, R., Willingham, M., Pastan, I., & Onda, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1477 · Cited by 296
Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6606 · Cited by 289
Tewari, D., Java, J. J., Salani, R., Armstrong, D. K., Markman, M., Herzog, T., Monk, B. J., & Chan, J. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9898 · Cited by 288
Screening for Ovarian Cancer: US Preventive Services Task Force Recommendation Statement
US Preventive Services Task Force, Grossman, D. C., Curry, S. J., Owens, D. K., Barry, M. J., Davidson, K. W., Doubeni, C. A., Epling, J. W., Kemper, A. R., Krist, A. H., et al. (2018) · JAMA · doi:10.1001/jama.2017.21926 · Cited by 283
Lengyel, E., Prechtel, D., Resau, J. H., Gauger, K., Welk, A., Lindemann, K., Salanti, G., Richter, T., Knudsen, B., Vande Woude, G. F., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.20598 · Cited by 273
EMT: Present and future in clinical oncology
Santamaria, P. G., Moreno‐Bueno, G., Portillo, F., & Cano, A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12091 · Cited by 259
Advanced Ovarian Cancer Trialists' Group, Aabo, K., Adams, M., Adnitt, P., Alberts, D., Athanazziou, A., Barley, V, Bell, D., Bianchi, U., Bolis, G., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.710 · Cited by 234
Wang, X., Ling, M. T., Guan, X.-Y., Tsao, S. W., Cheung, H. W., Lee, D. T., & Wong, Y. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207128 · Cited by 220
Ovarian cancer screening with annual transvaginal sonography: Findings of 25,000 women screened
van Nagell, J. R., DePriest, P. D., Ueland, F. R., DeSimone, C. P., Cooper, A. L., McDonald, J. M., Pavlik, E. J., & Kryscio, R. J. (2007) · Cancer · doi:10.1002/cncr.22594 · Cited by 217
Yoon, D., Osborn, M., Tolar, J., & Kim, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020340 · Cited by 215
Overexpression of theMET/HGF receptor in ovarian cancer
Di Renzo, M. F., Olivero, M., Katsaros, D., Crepaldi, T., Gaglia, P., Zola, P., Sismondi, P., & Comoglio, P. M. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910580507 · Cited by 212
Adoptive T-Cell Therapy for Cancer
Yang, J. C., & Rosenberg, S. A. (2016) · Advances in Immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 206
Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4567 · Cited by 198
A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer
Oronsky, B., Ray, C. M., Spira, A. I., Trepel, J. B., Carter, C. A., & Cottrill, H. M. (2017) · Medical Oncology · doi:10.1007/s12032-017-0960-z · Cited by 193
Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity
Power, A. T., Wang, J., Falls, T. J., Paterson, J. M., Parato, K. A., Lichty, B. D., Stojdl, D. F., Forsyth, P. A. J., Atkins, H., & Bell, J. C. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300039 · Cited by 191
Prognostic significance of c‐Met expression in glioblastomas
Kong, D., Song, S., Kim, D., Joo, K. M., Yoo, J., Koh, J. S., Dong, S. M., Suh, Y., Lee, J., Park, K., et al. (2009) · Cancer · doi:10.1002/cncr.23972 · Cited by 187
Rosanò, L., Cianfrocca, R., Spinella, F., Di Castro, V., Nicotra, M. R., Lucidi, A., Ferrandina, G., Natali, P. G., & Bagnato, A. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2325 · Cited by 187
Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer
Wright, A. A., Cronin, A., Milne, D. E., Bookman, M. A., Burger, R. A., Cohn, D. E., Cristea, M. C., Griggs, J. J., Keating, N. L., Levenback, C. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.4776 · Cited by 185
Olivier, R. I., Lubsen-Brandsma, M. A. C., Verhoef, S., & van Beurden, M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.038 · Cited by 180
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., & Hamilton, T. C. (1997) · PubMed · Cited by 178
Endothelin-1 Promotes Epithelial-to-Mesenchymal Transition in Human Ovarian Cancer Cells
Rosanò, L., Spinella, F., Di Castro, V., Nicotra, M. R., Dedhar, S., de Herreros, A. G., Natali, P. G., & Bagnato, A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2123 · Cited by 173
Chekmasova, A. A., Rao, T. D., Nikhamin, Y., Park, K. J., Levine, D. A., Spriggs, D. R., & Brentjens, R. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0192 · Cited by 171
Ovarian cancer creates a suppressive microenvironment to escape immune elimination
Yigit, R., Massuger, L. F. A. G., Figdor, C. G., & Torensma, R. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.01.019 · Cited by 168
Immunity over inability: The spontaneous regression of cancer
Jessy, T. (2011) · Journal of Natural Science, Biology and Medicine · doi:10.4103/0976-9668.82318 · Cited by 160
The role of immune checkpoint inhibition in the treatment of ovarian cancer
Gaillard, S. L., Secord, A. A., & Monk, B. J. (2016) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-016-0033-6 · Cited by 153
Rodriguez, G. M., Galpin, K. J. C., McCloskey, C. W., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080242 · Cited by 152
Ovarian cancer, the coagulation pathway, and inflammation
Wang, X., Wang, E., Kavanagh, J. J., & Freedman, R. S. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-25 · Cited by 135
Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers
Chang, X., Monitto, C. L., Demokan, S., Kim, M. S., Chang, S. S., Zhong, X., Califano, J. A., & Sidransky, D. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3427 · Cited by 129
Kandalaft, L. E., Powell, D. J., & Coukos, G. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-157 · Cited by 127
Role of copper transporters in platinum resistance
Kilari, D. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i1.106 · Cited by 124
The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin
Witham, J., Valenti, M. R., De-Haven-Brandon, A. K., Vidot, S., Eccles, S. A., Kaye, S. B., & Richardson, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0362 · Cited by 118
The role of survivin as a new target of diagnosis and treatment in human cancer.
Yamamoto, T., & Tanigawa, N. (2001) · Medical Molecular Morphology · doi:10.1007/s007950100017 · Cited by 110
Arulanandam, R., Batenchuk, C., Angarita, F. A., Ottolino‐Perry, K., Cousineau, S. E., Mottashed, A., Burgess, E., Falls, T. J., Silva, N. D., Tsang, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.009 · Cited by 108
MET Signaling Pathway: A Rational Target for Cancer Therapy
Appleman, L. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.7929 · Cited by 99
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 98
Barnett, J. C., Bean, S. M., Whitaker, R. S., Kondoh, E., Baba, T., Fujii, S., Marks, J. R., Dressman, H. K., Murphy, S. K., & Berchuck, A. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.11.020 · Cited by 96
Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma
Yen, M. J., Hsu, C.-Y., Mao, T., Wu, T. ‐., Roden, R. B. S., Wang, T., & Shih, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1397 · Cited by 96
Shah, C., Lowe, K. A., Paley, P. J., Wallace, E. R., Anderson, G. L., McIntosh, M. W., Andersen, M. R., Scholler, N., Bergan, L. A., Thorpe, J. D., et al. (2009) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-1034 · Cited by 94
Zeitlin, B. D., Zeitlin, I. J., & Nor, J. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7693 · Cited by 87
Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma
Creaney, J., van Bruggen, I., Hof, M. I., et al. (2007) · CHEST Journal · doi:10.1378/chest.07-0013 · Cited by 84
Januchowski, R., Sterzyńska, K., Zaorska, K., Sosińska, P., Klejewski, A., Brązert, M., Nowicki, M. O., & Zabel, M. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0278-z · Cited by 83
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
Wiggans, A. J., Cass, G. K. S., Bryant, A., Lawrie, T. A., & Morrison, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007929.pub3 · Cited by 76
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors
Dummer, R., Höeller, C., Grüter, I. P., & Michielin, O. A. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1967-1 · Cited by 71
Lanitis, E., Laniti, D. D., Hagemann, I. S., Song, D.-G., Best, A. J., Sandaltzopoulos, R., Coukos, G., & Powell, D. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049829 · Cited by 70
Provencher, D. M., Gallagher, C., Parulekar, W. R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx754 · Cited by 65
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics
McCloskey, C. W., Rodriguez, G. M., Galpin, K. J. C., & Vanderhyden, B. C. (2018) · Cancers · doi:10.3390/cancers10080244 · Cited by 64
Bosse, K., Rhiem, K., Wappenschmidt, B., Hellmich, M., Madeja, M., Ortmann, M., Mallmann, P. K., & Schmutzler, R. K. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.032 · Cited by 59
Uusi-Kerttula, H. K., Davies, J. A., Thompson, J., Wongthida, P., Evgin, L., Shim, K. G., Bradshaw, A. C., Baker, A. T., Rizkallah, P. J., Jones, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1089 · Cited by 51
Multiple Biomarker Panels For Early Detection of Ovarian Cancer
Yurkovetsky, Z. R., Linkov, F. Y., Malehorn, D. E., & Lokshin, A. E. (2006) · Future Oncology · doi:10.2217/14796694.2.6.733 · Cited by 50
Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish, J. B., & Jazaeri, A. A. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0504-y · Cited by 50
Ratner, E., Sartorelli, A. C., & Lin, Z. P. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3283564230 · Cited by 49
c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma
Kim, H.-J., Yoon, A., Ryu, J., Cho, Y., Choi, J., Song, S. Y., Bang, H., Lee, J. S., Cho, W. C. S., Choi, C. H., et al. (2016) · Scientific Reports · doi:10.1038/srep38502 · Cited by 41
Bandiera, E., Zanotti, L., Fabricio, A. S. C., Bucca, E., Squarcina, E., Romani, C., Tassi, R. A., Bignotti, E., Todeschini, P., Tognon, G., et al. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0151 · Cited by 36
Wang, H., Zhang, Z., Wei, X., & Dai, R. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0130-x · Cited by 36
Moro, F., Pasciuto, T., Djokovic, D., Legge, A. D., Granato, V., Moruzzi, M. C., Mancari, R., Zannoni, G. F., Fischerová, D., Franchi, D., et al. (2018) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.19174 · Cited by 33
Kuhn, I., Bauzon, M., Green, N. H., Seymour, L. W., Fisher, K. D., & Hermiston, T. W. (2016) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2016.12.001 · Cited by 28
Shewell, L. K., Wang, J. J., Paton, J. C., Paton, A. W., Day, C. J., & Jennings, M. P. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.001 · Cited by 28
Zhang, F., Throm, S. L., Murley, L. L., Miller, L. A., Zatechka, D. S., Guy, R. K., Kennedy, R. M., & Stewart, C. F. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.03.024 · Cited by 27
on behalf of the North-Eastern German Society of Gynecological Oncology (NOGGO), Sehouli, J., Camara, O., Schmidt, M., Mahner, S., Seipelt, G., Otremba, B. J., Schmalfeldt, B., Tesch, H., Lorenz-Schlüter, C., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0909-1 · Cited by 26
Ng, C. S., Zhang, Z., Lee, S. I., Marques, H. S., Burgers, K., Su, F., Bauza, J., Mannel, R. S., Walker, J. L., Huh, W. K., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1859 · Cited by 25
Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature
Diab, Y. M. S. K., & Muallem, M. Z. (2017) · Anticancer Research · doi:10.21873/anticanres.11631 · Cited by 23
Yellepeddi, V., Vangara, K. K., Kumar, A., & Palakurthi, S. (2012) · PubMed · Cited by 19
Cited by
Gajbhiye, K. R., Salve, R., Narwade, M., Sheikh, A., Kesharwani, P., & Gajbhiye, V. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01849-0 · Cited by 262
Metadata
- Authors
- Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R.
- Venue
- Cancer Medicine
- Publisher
- Wiley
- Published
- 2019-09-27
- Volume
- 8
- Issue
- 16
- Pages
- 7018-7031
- ISSN
- 2045-7634 (ISSN-L)
- OpenAlex
- W2975140046
- Cited by
- 449
- References
- 113
- FWCI
- 30.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.